$0.000001
Last update: Dec 10, 9:30 AM
Comments
Loading...
Latest Verus International Stock News | OTC:VRUS | Benzinga
Get the latest news on Verus International stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Verus International performance
Categories: All
Tuesday, January 12, 2021
Monday, December 28, 2020
Tuesday, January 24, 2012
Tuesday, January 17, 2012
Friday, January 13, 2012
Thursday, January 12, 2012
Wednesday, January 11, 2012
Tuesday, January 10, 2012
Monday, January 09, 2012
Friday, December 30, 2011
Tuesday, December 27, 2011
Friday, December 16, 2011
- Wedbush Securities Drops Coverage on Pharmass...
- Robert W. Baird Downgrades Pharmasset to Neutral
- Gilead Says it Remains Committed To Closing P...
- JP Morgan Overweight on Gilead Sciences After Pharmasset QUANTUM Trial Announcement
- Pharmasset Resumes Trading
- PREVIEW: Pharmasset to Resume Trading at 8:20...
- Pharmasset Announces Intent to Amend QUANTUM Trial
- Pharmasset Halted, News Pending
Tuesday, December 06, 2011
Monday, December 05, 2011
Thursday, December 01, 2011
Tuesday, November 29, 2011
Monday, November 28, 2011
Tuesday, November 22, 2011
- End-of-Day Market Summary for November 22, 2011
- UPDATE: Canaccord Downgrades Pharmasset to Hold, Ups PT to $137 on Announced Deal
- Brean Murray Downgrades Pharmasset to "Hold"
- Brean Murray Downgrades Pharmasset to Hold, Removes PT
- Wells Fargo Downgrades Pharmasset to Market Perform
- Leerink Downgrades Pharmasset to Market Perform
- A Peek Into The Market Before The Trading Starts
- Piper Jaffray Reiterates Overweight Rating on Achillion Pharmaceuticals
- Canaccord Downgrades Pharmasset to Hold
- UBS Downgrades Pharmasset to Neutral
- Benzinga's Top Downgrades
- UPDATE: JP Morgan Downgrades Rating to Neutral, Raises PT to $137 on Pharmasset
- Idenix and Spectrum Pharmaceuticals to Open Near 52-Week Highs
- JP Morgan Downgrades Pharmasset to Neutral, Raises PT to $137
Monday, November 21, 2011
- Pharmasset to Pay Gilead $331.9M Fee if Deal ...
- Pharmasset Agreed Not to Solicit Talks on Oth...
- Afternoon Movers; Healthcare Sector Up Significantly
- Hep-C Stocks Soar On M&A News
- What's Next for Hep C Drug Stocks Following Gilead's $11B Pharmasset Buy?
- UPDATE: Piper Jaffray Downgrades Pharmasset to Neutral, PT Raised to $137
